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Abstract
Background: A wide range of research areas in bioinformatics, molecular biology and medicinal 
chemistry require precise chemical structure information about molecules and reactions, e.g. drug 
design, ligand docking, metabolic network reconstruction, and systems biology. Most available 
databases, however, treat chemical structures more as illustrations than as a datafield in its own 
right. Lack of chemical accuracy impedes progress in the areas mentioned above. We present a 
database of metabolites called BioMeta that augments the existing pathway databases by explicitly 
assessing the validity, correctness, and completeness of chemical structure and reaction 
information.
Description: The main bulk of the data in BioMeta were obtained from the KEGG Ligand 
database. We developed a tool for chemical structure validation which assesses the chemical 
validity and stereochemical completeness of a molecule description. The validation tool was used 
to examine the compounds in BioMeta, showing that a relatively small number of compounds had 
an incorrect constitution (connectivity only, not considering stereochemistry) and that a 
considerable number (about one third) had incomplete or even incorrect stereochemistry. We 
made a large effort to correct the errors and to complete the structural descriptions. A total of 
1468 structures were corrected and/or completed. We also established the reaction balance of the 
reactions in BioMeta and corrected 55% of the unbalanced (stoichiometrically incorrect) reactions 
in an automatic procedure. The BioMeta database was implemented in PostgreSQL and provided 
with a web-based interface.
Conclusion: We demonstrate that the validation of metabolite structures and reactions is a 
feasible and worthwhile undertaking, and that the validation results can be used to trigger 
corrections and improvements to BioMeta, our metabolite database. BioMeta provides some tools 
for rational drug design, reaction searches, and visualization. It is freely available at http:// 
www.cmbi.ru.nl/biometa/ provided that the copyright notice of all original data is cited. The 
database will be useful for querying and browsing biochemical pathways, and to obtain reference 
information for identifying compounds. However, these applications require that the underlying 
data be correct, and that is the focus of BioMeta.
Open Access
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Background
The importance of knowledge about metabolites for 
understanding life is well demonstrated by their promi­
nent role in the Kyoto Encyclopedia of Genes and 
Genomes [1-5], MetaCyc[6], the Boehringer-Mannheim 
charts[7,8], Brenda[9,10], ExPASy[11], ChEBI[12], or 
PubChem[13]. These databases vary considerably in their 
focus. Some have a strong emphasis on enzymatic infor­
mation, while others are metabolic databases containing, 
for example, information about metabolites, reactions, 
enzymes, and genes. Most of these systems also contain a 
limited number of small xenobiotic compounds.
Three frequently used pathway databases are KEGG, Met- 
aCyc, and Brenda. KEGG is a suite of databases and asso­
ciated software, interlinking data on small compounds, 
reactions, enzymes, and genes. The graphical pathway 
maps to which the databases are linked are an important 
feature of KEGG. MetaCyc[6] is a curated database of 
experimentally elucidated metabolic pathways from 
many organisms. It contains data about pathways and 
their associated small compounds, enzymes, and genes. 
KEGG and MetaCyc both contain data on metabolites; 
unfortunately, MetaCyc does not hold atomic informa­
tion on small compounds. The metabolite data in KEGG 
(the Compound section of the Ligand database) have 
been organized such that they are easily downloadable as 
chemical structure files in the MDL molfile format[14].
The Boehringer-Mannheim wall charts[7] offer a glimpse 
on the enormous complexity of the interlinked metabolic 
network. The small-molecule part of these charts has been 
extracted into a C@rol[15] database called BioPath[16]. 
Brenda[10] is a curated enzyme database that provides 
pictures of reaction diagrams and chemical structures of 
small compounds. ChEBI[12] is a dictionary of molecular 
entities focusing on small compounds. PubChem[13] is a 
database of chemical structures of small compounds and 
information on their biological activities. Many of these 
databases, especially ChEBI and PubChem, contain cross­
references to other databases, notably KEGG. PubChem 
merely lists these references, but in ChEBI the entries are 
curated and classified using a chemical ontology.
Even though the systems mentioned above provide a 
wealth of data, they cover only a very small portion of all 
possible metabolites. Estimates on the total number of 
metabolites range from 200,000[17] to about 
1,000,000[18], but even this higher estimate may be con­
servative. If plant and bacterial secondary metabolites 
(metabolites that are not necessary to keep the organism 
alive) are included then the numbers are enormously 
larger. The probable number of metabolites is also consid­
erably larger than the number of corresponding 
genes[19], so it seems that the currently available data­
bases cover at best 2% of the total number of metabolites. 
Of course, this discussion includes only metabolites from 
biochemical pathways, not the catabolism of xenobiotics
-  the number of small compounds involved in those proc­
esses may go up indefinitely as many thousands of xeno- 
biotics are being developed every year.
The limited availability of metabolite data stands in 
marked contrast to the high demand for them. A wide 
range of research areas in bioinformatics, molecular biol­
ogy, and medicinal chemistry require chemical structure 
information about molecules and reactions. This need is 
best seen for fields like total synthesis of natural products, 
drug design, ligand docking, metabolomics, metabolic 
network reconstruction, or systems biology. Metabolites 
have been used in several ways in drug design. First, 
endogenous human metabolites can be used as leads in 
drug design. Second, many metabolites from plants or 
other sources are medicines or good leads for drug 
design[20]. All such applications require the molecular 
information to be correct, complete, and accurate. We 
have therefore set out to design and implement BioMeta, 
a database that aims at providing correct metabolite struc­
tures and correct reactions. The philosophy behind the 
correction principles is that enzymes cannot invent new 
chemistry; they can only speed up existing chemistry. So, 
if a metabolic conversion does not make sense from an 
organic chemistry point of view, it also does not make 
sense from a metabolic point of view.
Structure descriptions of compounds can be checked 
automatically for incorrect valences and undefined stere­
ocenters, and reactions can be checked automatically for 
incorrect stoichiometry. Once a structure description is 
administratively correct and completely defined, further 
error checking (incorrect composition, connectivity, or 
stereochemistry) will require manual inspection and com­
parison to other sources, e.g., original references and other 
compounds related to it through known reactions. How­
ever, even for the automatic validations, no general tools 
are currently available, so we developed them specially for 
BioMeta.
BioMeta is a relational database containing information 
about known metabolites and the validation of their 
structures. It also holds metabolic reactions. It is based 
entirely on freely available metabolite data (mainly from 
KEGG) and is freely available as a web service[21] (pro­
vided that the copyright notices of the original data pro­
viders are respected).
Construction and C ontent 
BioM eta database design
The main ideas behind BioMeta's database design are sim­
ilar to those in the KEGG Ligand database. BioMeta's
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major tables hold compounds (molecules), reactions, 
enzymes, and references (literature and other sources). A 
series of relation tables connect these elementary data. 
Two relations are pivotal: 1) reactions are described in 
terms of participating molecules (and a molecule has a 
particular role in a reaction); and 2) enzymes catalyze one 
or more reactions (and a reaction is catalyzed by one or 
more enzymes). No direct relation exists between com­
pounds and enzymes -  they are only linked indirectly 
through reactions. At present, only two roles are used: 
reactants and products -  these are simply the compounds 
on the left- and right-hand sides of the reaction arrow. 
(Note that the term "reactant" appears to be used differ­
ently by chemists and biologists. Chemists use it as a syn­
onym for the rarely used term "educt"; some biologists 
seem to use it to indicate "either substrate or product". We 
avoid the term "substrate" since both reactants and prod­
ucts can be substrates of an enzyme, and the term loses its 
meaning if the reaction is not catalyzed.) The database 
design allows compound roles such as inhibitor and acti­
vator to be added easily. Figure 1 shows an outline of the 
database design and the most important data tables. 
Compounds and enzymes have much in common, so 
both tables contain similar data fields: CAS registry 
number, (common) name, systematic name, references to 
other databases (be it KEGG accession numbers or EC 
numbers). PostgreSQL does not allow arrays of values 
(multiple values) for a given data field. For each such field 
a separate table must exist which is linked (through the 
entry IDs) to the corresponding main table. Since both
compounds and enzymes usually have a number of differ­
ent names, these synonyms are stored in separate syno­
nym tables. For both compounds and enzymes, there is a 
second synonym table (not shown in Figure 1) containing 
so-called "fuzzy" synonyms in which are non-alphanu- 
meric characters have been removed and all letters have 
been converted to upper case. These extra tables allow 
"fuzzy" synonym searches.
The reactions table contains information pertaining to 
reactions as a whole, such as reversibility, balance, or the 
KEGG accession number. The relations between mole­
cules and reactions are stored in the Rxn-Mol link table, 
each row in this table describing the role (reactant, prod­
uct) and stoichiometry of a particular molecule in a par­
ticular reaction. The relations between reactions and 
enzymes are stored in the Rxn-Enz link table; each row in 
this table indicates that a particular enzyme catalyzes a 
particular reaction. The database does not contain other 
information about pathways or pathway maps, nor does 
it contain gene, species, or cellular localization informa­
tion.
An additional data table (not shown in Figure 1) is used 
to store molecular formula information. This table con­
tains the appropriate coefficient for each compound/ele­
ment combination (e.g., the 2 in H2O). The field 
ElemCount in the Compounds data table contains the 
number of different elements in the formula of a com­
pound. In combination, they allow formula searches such
Compounds
CAS reg. nr. 
Name 
KEGG ID 
ElemCount
Reactions Enzymes
Mol-Synonyms
Reversibility 
Description 
KEGG ID
Rxn-Mol
CAS reg. nr. 
Name 
EC number
Rxn-Enz Enz-Synonyms
Synonym Role
Stoichiometry
Synonym
Figure 1
Outline o f the BioMeta database design, showing the main tables and the m ost im portan t link tables. The main 
tables are Compounds, Reactions, and Enzymes. The most important link tables are displayed in purple. The "green" tables 
contain synonyms (for both compounds and enzymes). For clarity, data fields of lesser importance have been omitted.
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as "all compounds with twenty carbon atoms and at least 
38 hydrogen atoms and at most three different elements".
Compounds and reactions in the K EG G  Ligand database
The KEGG metabolic pathways are graphical maps dis­
playing compounds and reactions from the Ligand data­
base [1-4]. This Ligand database is tightly coupled to the 
KEGG pathway maps. It consists of three sections: Com­
pound, Reaction, and Enzyme. The Compound section 
contains about 13,000 small compounds, most of which 
are involved in enzymatic reactions as substrates, prod­
ucts, cofactors, or inhibitors. A number of drugs and xeno- 
biotics have also been included but these are currently 
being transferred to a separate Drug section in the KEGG 
Ligand database. Each compound entry contains an ID 
code, CAS registry number, common name, synonyms, 
systematic name, chemical formula, structure as an MDL 
molfile[14] with a GIF image, reaction links, and enzyme 
links. The Reaction section contains about 6,500 reac­
tions. Each reaction entry contains an ID code, name of 
the enzyme, a textual description of the reaction, chemical 
structures of the substrates and products as an MDL rxn- 
file[ 14] and as a GIF image, an equation expressed in com­
pound ID codes, links to Enzyme entries, and a link to the 
corresponding KEGG pathway map. The rxnfiles are con­
structed from the molfiles of the participating com­
pounds. The Enzyme section (about 4,500 entries) 
contains the enzymes, indexed by their EC number. The 
majority of entries (compounds, reactions, and enzymes) 
in BioMeta were obtained from KEGG.
We obtained the compounds from the KEGG Ligand data­
base as molfiles. These molfiles contain structural infor­
mation in a so-called 2D representation, meaning that the 
drawings are primarily intended to show the constitution
(connectivity) of the molecules; 3D information is absent. 
Hydrogen atoms are usually omitted unless they are used 
to indicate the stereochemical configuration. The configu­
ration of stereocenters is indicated using wedged and 
dashed bonds as is common in organic chemistry. In prin­
ciple, these 2D structure representations are sufficient for 
the chemical identification of compounds. Unfortunately, 
not all structures are provided with stereochemical detail. 
Four examples of commonly observed deviations are 
shown in Figure 2. Sometimes the configuration of a ster­
eocenter is omitted (e.g., C01569). The stereochemistry of 
the base skeleton is sometimes left out because it is con­
sidered to be commonly known (e.g., steroids such as 
C05455). In a number of structures (mostly carbohy­
drates such as C01488) the stereochemistry is described 
using a Fischer projection. In other cases a perspective 
drawing has been used (e.g., C00729). While these differ­
ent styles of representation can usually be correctly inter­
preted by a knowledgeable chemist, they have no 
meaning within the molfile format, and any software 
processing such molfiles cannot function reliably. In par­
ticular, a 3D model building program would assign ran­
dom configurations to undefined stereocenters; or worse, 
that software might crash.
Lack of stereochemical completeness may also prevent 
database normalization. When a compound is entered in 
a relational database, duplicate checking must prevent 
redundant entries. If the new structure is actually the same 
as one already present in the database but it is not com­
pletely described, the duplicate check is likely to fail and a 
new compound entry is wrongly introduced. In the case of 
metabolic modeling, incomplete or erroneous networks 
may be built because the chemical identity of two com­
pounds from different reactions goes undetected.
Figure 2
Sample structures from  KEGG w ith  incomplete stereochemistry. Undefined stereocenters are indicated by an aster­
isk. C01569: undefined; C05455: defined by convention (cholestane skeleton); C01488: defined using Fischer projection; 
C00729: defined using perspective drawing.
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Even when chemical structures are represented correctly 
and completely, structure representation may be compli­
cated because in physical reality a compound may consist 
of a dynamic mixture of rapidly interconverting struc­
tures. Two important types of such behavior are tautomer- 
ism and anomerism. In the case of tautomerism, acidic 
hydrogen atoms may wander freely over basic sites. The 
imidazole ring in histidine is a familiar example. Anomer- 
ism, which is common with carbohydrates, is the reversi­
ble opening and closing of ring forms (mainly pyranoses 
and furanoses). The ring forms, which predominate in 
solution, may exist in two different stereoisomeric forms 
called alpha and beta (Figure 3). The treatment of tautom- 
erism and anomerism is far from trivial and will be dis­
cussed in a separate publication.
We obtained the reactions from the KEGG Ligand data­
base in the form of an ASCII file. This file does contains 
neither information about reversibility nor, if irreversible, 
about the direction of the reactions. Reversibility/direc­
tion information is obtained from a separate ASCII file 
which KEGG maintains in connection to their graphical 
maps. Another important issue is the reaction balance that 
indicates whether an equal number of atoms of the vari­
ous elements and an equal number of charges is present 
on both sides of the reaction arrow. The KEGG Reaction 
section of the Ligand database contained 6089 reactions, 
of which 5323 were provided with fully described and 
non-polymeric structures. The other 766 reactions either 
had missing structures (e.g., "acceptor" or "phosphor- 
ylated protein") or involved polymeric compounds (e.g., 
"oligopeptide" or "starch"), preventing assessment of 
their balance. We found that 3711 reactions were bal­
anced and that 1612 were unbalanced. Unbalanced reac­
tions can obviously not be used for the automatic 
construction of reaction networks as is done in metabolic 
modeling and systems biology. It is an easy matter to 
identify the unbalanced reactions, but a major problem to
correct them. The cases where just a simple component 
such as H+, H2O, CO2, or H3PO4 is missing could be ame­
nable to automatic correction. Most cases, however, will 
require tedious manual correction. Using an automatic 
procedure, we have corrected the reactions where the 
"imbalance" was H2O, H+, or 2H+, accounting for 893 
reactions (55% out of 1612) reactions. Limited resources 
have prevented us from making a more thorough attempt.
Chemical structure validation software
Many biologists, bioinformaticians, and other researchers 
in related areas usually identify a compound by name. To 
chemists, the identity of a compound is normally deter­
mined by its 2D structure. Incorrect 2D structures cannot 
be linked to actual chemical species, and incomplete ones 
(those lacking full stereochemical detail) cannot be linked 
to a unique one. We have written validation software that 
checks the correctness and completeness of structure 
descriptions (i.e., molfiles) of small compounds. It per­
forms the following tasks:
1. Determining and checking valency;
2. Ring and aromaticity detection;
3. Calculation of molecular formula, weight, and exact 
mass;
4. Stereochemistry detection;
5. Canonicalization;
6. Calculation of canonical string identifiers.
MDL molfiles describe 2D chemical structures in a 
valence-bond representation. Valences can therefore be 
checked using the Lewis structure concept (i.e., the 
number of electrons in the valence shell of first-row ele­
Figure3
Different variants o f D-glucose w ith  th e ir  names and KEGG accession codes. The a -  and P-D-glucopyranose forms 
account for 37% and 63% respectively of the equilibrium mixture in aqueous solution. The open form, absent from KEGG, is 
present in small amounts. The D-glucofuranose forms (five-membered rings) are not shown, as they are only present in insig­
nificant amounts. The fact that C0003I represents the equilibrium mixture of C0022I and C00263 causes a problem in consist­
ency of database management of these compounds.
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ments is usually eight and can only be less, never more). 
As a rule, the structures are hydrogen-suppressed (hydro­
gen atoms occur only when needed to indicate stereo­
chemical configurations), so the valence detection will 
give the numbers of (implicit) hydrogen atoms on each 
atom which, of course, needed for the calculation of the 
molecular formula and weight.
Rings are detected primarily to be able to detect aromatic- 
ity. Without aromaticity detection, the two Kekulé struc­
tures for ortho-xylene would be considered isomeric 
(Figure 4). Aromaticity detection was restricted to ben­
zene-type rings (pyridine, pyrimidine, etc.) and pyrrole- 
type rings (thiophene, imidazole, oxazole, etc.) and all 
their fused combinations.
All carbon, nitrogen, and phosphorus atoms having four 
single bonds (or three plus one to an implicit hydrogen) 
are treated as potential stereocenters. An atom is a stereo­
center if its inversion would change the molecule into a 
different stereoisomer (determined by the canonicaliza- 
tion routine described below). If it is not a stereocenter, 
any stereo bonds (wedges or dashes) on it are ignored; if 
it is, its configuration is determined based on the stereo 
bonds present (the absence of such bonds indicating an 
undefined stereocenter). Note that not all arrangements 
of stereo bonds around a center are meaningful (Figure 5).
Similarly, C = C, C = N, and N = N double bonds were 
examined for possible cis/trans isomerism, excluding aro­
matic double bonds and those in cumulenes such as 
allenes. A bond is a stereo double bond if its "inversion" 
(cis-trans isomerization) would change the structure into 
a different stereoisomer. The 2D coordinates suffice for 
establishing the configuration. Only if one of the atoms 
on the bond is singly substituted and the bond angle at 
that atom is 180 degrees can the stereochemistry of a dou­
ble bond remain unknown, i.e., undefined (Figure 5). 
Finally, the program determines whether the molecule is 
chiral. A molecule is chiral only if it is not superimposable 
onto its mirror image. The mirror image is easily obtained 
by inverting all stereocenters. If the mirror image is not 
identical to the original molecule (determined by the 
canonicalization routine described below), then the mol­
ecule must be chiral. If the structure in a molfile is chiral, 
the intended structure may be the enantiomer as it has 
been drawn (absolute stereochemistry) or it may be the 
racemic mixture of that structure (relative stereochemis­
try) or, perhaps, a single but unknown enantiomer. In the 
molfile this is indicated through the so-called "chiral 
flag"[14] which is set to 1 in the case of absolute stereo­
chemistry. If a structure is chiral, but the flag has not been 
set to 1 in the molfile, the validation program issues a 
warning -  since for the purpose of a biochemical data­
base, the intended structure is expected to be a single, 
known enantiomer.
Canonicalization is the unique numbering of atoms in a 
molecular structure. It helps to uniquely identify a mole­
cule, independently of how it is drawn. We implemented 
a canonicalization method based on the Morgan algo- 
rithm[22] similar to the SEMA (stereochemically 
extended Morgan) algorithm[23]. Canonicalization and 
stereochemistry detection are performed simultaneously 
because the identity of two molecular representations 
may have to be assessed during stereochemistry detection 
(see the preceding section). The canonicalization routine 
generates a string that can be used for text-based identity 
checking and hence for structure matching. This "unique" 
string is similar in nature to strings such as the SEMA 
name[23], unique Smiles[24], PRODRG molecular 
descriptor string[25], and InChI[26]. A second "unique" 
string is calculated the same way but neglecting stereo­
chemistry. This second string can be used to search for
Figure4
The two Kekulé structures (mesomeric forms) for ortho-xylene.
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Correct stereocenters Ambiguous stereocenters Ambiguous stereo bond
A ^ . B  A ^ B  
C D  ( ƒ  D |
AV ^ B A \ >> B
A A  a
A
> =  c  
B
Figure 5
Valid and invalid (ambiguous) representations of sp3 (tetrahedral) stereochemistry and double bond stereochemistry.
stereoisomers. Figure 6 shows the canonically numbered 
structure of L-threonine and a number of calculated data 
fields such as the number of stereocenters and double 
bonds, the unique strings mentioned above, the molecu­
lar formula and weight, and the M/Z peak based on 100% 
abundance of the most common isotopes.
Validation o f compounds and reactions from the K EG G  
Ligand database
BioMeta was intended to be complementary to the KEGG 
Ligand database by focusing on the application of organic 
chemical knowledge to small compounds, thus ensuring 
that the compounds and implicitly the reactions are cor­
rect. Hundreds of molecular structures were corrected or 
improved. Table 1 gives a breakdown of the validation 
results and the corrections made in the 12,815 molecule 
entries present in both BioMeta and the KEGG Ligand 
compound section of October 25, 2005. The validation 
program can detect only syntactical problems, e.g.,
valence violations, undefined enantiomer, or invalid ster­
eochemistry. Some are real errors requiring correction, 
such as a missing structure (if it is not polymeric or 
generic), valence violations, or ambiguously drawn stere­
ocenters. Problems in the "undefined" categories suggest 
incomplete structural information, but not all such cases 
are necessarily incorrect, e.g., a drug that is a racemic com­
pound would trigger the warning "unspecified enanti­
omer". Problems in the "incorrect" categories have not 
been detected by the validation program since these errors 
are semantic rather than syntactic -  they were detected 
through visual inspection. A total of 1468 structures were 
corrected. The large majority of valence errors involved 
nitrogen atoms that were not trivalent. The most common 
of these were: 1) a nitrogen atom having one double bond 
and two single bonds, but no charge (i.e., intended to be 
a pyridinium- or nitro-type nitrogen), these were cor­
rected by removing an attached hydrogen or else by add­
ing a positive charge, and 2) coordinative bonds from a
Figure6
Canonically numbered structure and calculated data fields fo r L-threonine. NM = (common) name, ST = absolute/ 
relative stereochemistry, SD = number of defined stereocenters, SU = number of undefined stereocenters, BD = number of 
defined double bonds, BU = number of undefined double bonds, RC = number of rings, US = unique string (stereochemistry 
included), UC = unique string (stereochemistry excluded), MF = molecular formula, MW = molecular weight, MZ = M/Z peak 
with abundance.
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imine-type nitrogen to a metal indicated as covalent. 
Unfortunately, the molfile format[14] does not support 
coordinative bonds, so these bonds had to be removed. 
Table 2 gives a more detailed breakdown of the sp3 stere­
ochemistry enhancements from Table 1 (the numbers are 
slightly different because double-bond stereochemistry is 
omitted). In Table 2 the "unspecified enantiomer" cases 
from Table 1 are split between two "relative" stereochem­
istry cases, incompletely and completely defined. All cases 
(also for meso compounds) are listed so that the numbers 
add up.
We also assessed the balance (stoichiometry) of the reac­
tions. BioMeta contains 5323 reactions with fully 
described and non-polymeric structures, of which 3711 
were balanced and 1612 were unbalanced. We also deter­
mined the "imbalance" of these reactions and those for 
which the imbalance was H2O, H+, or 2H+ were corrected, 
accounting for 893 reactions (55% out of 1612) reactions. 
Limited resources prevent us from making a more thor­
ough attempt.
KEGG version 3.6 contained the reaction "Fe + O2 + 4 H+ 
<=> Fe + 2 H2O" which prompted us to manually review 
all metal cations in the database. A number of those were 
present as "generic" cations, without an actual charge 
specification. To remedy this situation, six metal cations 
having definite oxidation states (Mn3+, Mn2+, Fe3+, Fe2+, 
Co3+, and Cu+) were added. Co2+ and Cu2+ were already 
present in KEGG. In the meantime, KEGG has also carried 
out this correction for the iron cations (in version 3.8) but 
not for manganese.
T a b le  1: D e te c te d  and c o r re c te d  p ro b le m s  in th e  B io M e ta
T y p e  o f  P ro b le m #  in  K E G G
Structure missing 1239
Valence violation(s) 76
Inco rrec t constitu tion unknown
T o ta l ( c o n s t itu t io n ) 1315
Undefined stereo double bond(s) 35
Invalid sp3 stereocenter(s) 70
Ambiguous sp3 stereocenter(s) 46
Undefined sp3 stereocenter(s) 1398
Unspecified enantiom er 2326
Undefined sp3 stereochem istry 554
Inco rrec t stereochem istry unknown
T o ta l (s te re o c h e m is try ) 3990
T o ta l c o r re c te d
A variety of methods was used to determine the correct or 
intended structure. The name often provided sufficient 
information, but in many cases the reactions in which a 
compound was involved had to be consulted; either in the 
KEGG database or in other databases such as 
Brenda[9,10], MetaCyc[6], or ExPASy[11]. In the cases 
where database information was insufficient and the orig­
inal literature had to be consulted. Brenda proved most 
useful for obtaining those references. We will discuss three 
examples of database corrections to illustrate the kinds of 
problems encountered, but also to illustrate the impor­
tance of these corrections for, e.g., systems biology.
Examples o f validations and corrections
Example 1
Reaction entry R03577 from KEGG (Figure 7) is the 
reversible reduction of D-apiose (C01488) by NADH to 
give D-apiitol (C01569, see also Figure 2). The reaction 
itself is correct, but the structures are stereochemically 
undefined. Moreover, the structure of C01569 is wrong -  
it lacks a hydroxyl group at the branched carbon, which is 
only apparent after inspection of the reaction and com­
parison to D-apiose. Alternatively, a name search for apii- 
tol in either the Beilstein[27] or CAS [28] databases will 
confirm the correct structure. To establish the intended 
stereochemistry, the prefixes "D-" in the compound 
names suffice.
Example 2
Riboflavin is biosynthesized from 6,7-dimethyl-8-(1-D- 
ribityl)-lumazine, which in turn is biosynthesized from 5- 
amino-6-(5-phosphoribitylamino)uracil and D-ribose 5-
#  in  B io M e ta  #  C o r re c te d
1 106 133
0 76
unknown 107
1106 316
32 3
47 23
0 46
865 533
1840 486
366 188
unknown 69
2907 1 152
1468
The table shows the validation and correction results o f 12,815 entries present in both the KEGG Compound (version o f O ctober 25, 2005) and 
BioMeta databases. N ote  tha t the absence o f a s tructure does no t need to  be an e r ro r -  i t  may be a generic compound such as "acceptor" o r 
"phosphorylated prote in". Likewise, no t all "unspecified enantiom er" cases need to  be e rro rs  -  a number o f drugs may be racemic compounds. The 
ro w  "total (stereochem istry)" is no t the sum o f the preceding cases because compounds may have multip le problems. The rows w ith  the tota ls do 
n o t add up because o f the "unknown" entries -  if these numbers w ere known then the numbers would add up.
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T a b le  2: S ta tis tic s  o f  sp3 s te re o c h e m ic a l c o n te n t in  th e  K E G G  C o m p o u n d  and B io M e ta  da tabases
S te re o c h e m is try O K #  in  K E G G #  in  B io M e ta #  C o r re c te d
N o t possible + 3725 3764
Undefined (i.e., om itted) - 554 366 I88
Incompletely defined -  meso - 24 3 2I
Incompletely defined -  absolute - I080 69I 389
Incompletely defined -  relative - 294 I7 I I23
C om pletely defined -  meso + 56 89
C om pletely defined -  absolute + 3735 4823
C om pletely defined -  relative - 2O32 I669 363
T o ta l n o t  O K 3984 2900 1084
T o ta l O K 7 5 I6 8676
T o ta l I I5 0 0 11576
The numbers in this table give a m ore detailed breakdown o f the sp3 stereochem istry enhancements from  Table 1. Here "O K " means a single, 
com pletely defined, compound. The "unspecified enantiom er" cases from  Table 1 are split here between tw o  "relative" stereochem istry cases, 
incom pletely and com pletely defined. N ote  tha t no t all "Com plete ly defined -  relative" cases need to  be e rro rs  -  a number o f drugs may be racemic 
compounds.
Figure7
KEGG reaction entry R03577 w ith  corrected structures. The configurations of the stereocenters were inferred from 
the names of the compounds. Note that the branched carbon in D-apiitol (C00I569) is symmetrically substituted and there­
fore not a stereocenter. This remains the case after addition of the hydroxyl group.
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phosphate. The latter process is present in the KEGG lig­
and database as a single reaction (entry R04457, see Fig­
ure 8). This representation suffers from a number of 
problems, the most important being the imbalance in car­
bon, phosphorus, oxygen, and hydrogen. Moreover, the 
lumazine product is shown on the left-hand side of the 
reaction arrow. Since the actual process comprises four 
separate reaction steps[8], it seemed prudent to replace 
reaction entry R04457 by these four steps. In fact one of 
these steps (MR005453 in Figure 8) is already a quite 
complicated reaction by itself[29]. KEGG and BioMeta 
already contained the conversion of D-ribose 5-phos­
phate into D-ribulose 5-phosphate (KEGG entry R01056/ 
BioMeta entry MR000958) so only the three reactions in 
Figure 8 had to be added to BioMeta.
Example 3
The monoterpene 1,8-cineole is metabolized through (+)- 
2endo-hydroxy-1,8-cineole which in turn is degraded in 
two steps to (R, R)-1,6,6-trimethyl-2,7-dioxobicyclo- 
[3.2.2]nonan-3-one (Figure 9). The first of these steps 
looked rather odd in KEGG (entry R02994). A regular 
dehydrogenation by NAD+ would be expected to produce 
a keto group at the same position as the original hydroxyl 
group. The same reaction in Brenda suggested that the 
ketone in KEGG was wrong, but now the next step, the 
oxygen insertion, looks very strange in Brenda. In KEGG 
this step (entry R02995) seems correct, a simple insertion 
of an oxygen into a C-C bond adjacent to a keto group 
(Baeyer-Villiger type oxidation). Further checking 
revealed[30] that in both databases the alcohol com­
pounds were wrong and in Brenda the ketone as well. The 
compounds were corrected in BioMeta (Figure 9) with the 
correct stereochemistry[30].
Database implementation details
The BioMeta database was implemented in Post- 
greSQL[31], an open-source relational database manage­
ment system. Its contents are also stored in text (ASCII) 
files, and Python[32] scripts have been written to import 
these files into the database and to export the database 
contents into the text files. When the database is being 
filled, the output from the chemical validation software is 
included in the database import. The validation software 
has been written in Fortran. Python scripts have also been 
used for the web interface.
U tility  and Discussion 
Web interface
The database can be accessed through a web interface (Fig­
ures 10 and 11). Structures can be searched as exact struc­
ture (with or without stereochemistry taken into account), 
by name (with or without non-alphanumeric characters 
taken into account, called "fuzzy match" in the interface), 
by KEGG accession code, CAS registry number, molecular
formula, molecular weight, or exact mass (calculated from 
the most abundant isotope for each element). A Java 
applet called JME (Java Molecular Editor)[33] is used to 
draw the structure queries (and to display structures from 
the database). All string fields allow substring searching 
using wildcards (asterisks), all numeric fields allow com­
parison and range searching (e.g., molecular weight 
123.2-123.9), and all search options can be combined in 
a logical "and" fashion. Name searches are conducted in 
the synonym tables. When a compound is displayed, a 
hyperlink is available to search for all reactions in which 
it is involved. Similarly, when a reaction is displayed 
hyperlinks are available to 1) search for all enzymes which 
catalyze it; and 2) access each molecule involved in the 
reaction, and when an enzymes is displayed a hyperlink is 
available to search for all reactions that it catalyzes. The 
interface allows to follow biochemical pathways quite 
quickly and efficiently, also because different browser 
windows are used for compounds, reactions, and 
enzymes.
In addition to the various data fields calculated from the 
structure, The web interface displays the various data 
fields calculated from the structures and the reaction, 
including the validation results. For compounds, the ster­
eochemical information (field "Stereochemistry") is dis­
played with respect to completeness: "None" if the 
compound cannot exhibit stereoisomerism, "None (i.e., 
undefined)" if stereoisomerism is possible but stereo­
chemistry is completely absent, "Meso" if the compound 
is achiral, "Relative" if the compound is chiral but a 
racemic mixture is indicated (this may or may not be 
intentional, drugs are often racemates), and finally "Abso­
lute" if the compound is chiral and the enantiomer shown 
is the intended one. "Meso", "Relative", and "Absolute" 
may be followed by the remark "partially defined" if one 
or more stereocenters are undefined. For reactions, the 
field "Balanced" indicates whether the reaction is bal­
anced or not. In case of an unbalanced reaction the word 
"No" is followed by a chemical formula representing the 
difference between the reactants and products). If one or 
more compounds have a polymeric structure or do not 
have a structure at all, the balance is displayed as 
"Unknown".
We expect that BioMeta will prove useful for querying and 
browsing biochemical pathways, to search connecting 
reaction paths between metabolites, and to view (calcu­
lated) three-dimensional models of the structures, to 
obtain reliable molecular data on metabolites, etc. Three­
dimensional structures (calculated by Corina[34]) are 
already available for compounds with stereochemically 
completely defined structures. In the future, BioMeta may 
also provide the basis of several inference engines. For 
example, graph-theoretical approaches can be applied to
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Figure8
The biosynthesis o f 6,7-d im ethyl-8-(l-D -rib ity l)-lum azine from  5-amino-6-(5-phosphoribitylamino)uracil and 
D-ribose 5-phosphate in KEGG and in BioMeta. Reaction entry R04457 from KEGG is shown with the problems indi­
cated, including the product being shown on the left-hand side. The carbon and phosphorus imbalance causes the reaction to 
be unbalanced in oxygen and hydrogen as well. In BioMeta three reaction steps have been added to correctly represent this 
chemistry. Note that the reaction from D-ribose 5-phosphate to D-ribulose 5-phosphate (the reactant of MR005453) was 
already present in the database.
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Figure9
The tw o reaction steps leading from  (+)-2endo-hydroxy-l,8-cineole to  (R, R)-l,6,6-trimethyl-2,7-dioxobicyclo- 
[3.2.2]nonan-3-one in the BioMeta, KEGG (entries R02994 and R02995), and Brenda databases. Incorrectly posi­
tioned oxygen groups are indicated by red arrows. Note that the structures from both KEGG and Brenda lack stereochemis­
try.
determine pathways from series of individual enzymatic 
reactions[35].
Conclusion
We demonstrate that the validation of metabolite struc­
tures and reactions is a feasible and worthwhile undertak­
ing, and that the validation results can be used to trigger 
corrections and improvements to BioMeta, our metabo­
lite database. BioMeta provides some tools for rational 
drug design, reaction searches, and visualization. The 
database will be useful for querying and browsing bio­
chemical pathways, and to obtain reference information 
for identifying compounds, and for all other applications 
that require the underlying molecular data to be correct.
We have made our corrections available to KEGG and will 
keep doing so for the foreseeable future.
Availability and requirem ents
The BioMeta database is freely available as a web serv­
ic e l i ]  provided the copyright notice of all original data is 
cited. The restrictions for use of the database are the same 
as those for the use of the KEGG Ligand database. Aca­
demic users may freely use the web site. Non-academic 
users may also use the web site as end users, but any form 
of distribution is not allowed.
The interface makes use of the JME (Java Molecular Edi- 
tor)[33] to display structures and to draw structure que­
ries, so the browser needs to be Java-enabled.
Project name: The BioMeta Database
Project home page: http://www.cmbi.ru.nl/biometa/
Page 12 of 15
(page number not for citation purposes)
BMC Bioinformatics 2006, 7:517 http://www.biomedeentral.eom/1471-2105/7/517
Figure 10
A  snapshot o f the compound query menu o f the BioMeta web interface. The top row buttons lead to the four main 
search domains. The JME Molecular Editor is used to draw structure queries, optionally ignoring stereochemistry. The Name 
box allows searches for synonyms, optionally ignoring case and punctuation ("fuzzy" matching). ID and CAS # allow searches 
for BioMeta ID and CAS registry number, resp. Element Count and Molecular Formula allow extensive formula queries. The 
External links field allows searches for KEGG accession number. Note that all text fields allow queries using wildcards, all 
numerical fields (Element Count, Molecular Weight, and Exact Mass) allow comparison and range queries, and all query options 
can be combined.
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Figure 11
The BioMeta web interface fo r reactions. 'Description' contains the KEGG Definition string, 'ID' the BioMeta ID, 'Bal­
ance' the reaction balance (yes, no, or unknown) and 'Direction' the direction of the reaction (right, left, reversible, or 
unknown) which is also expressed by the reaction arrow. The substrates and products of the reaction can be directly accessed 
through hyperlinks, as can the enzyme(s) catalyzing the reaction. The hyperlink following 'external links' gives access to the 
corresponding KEGG reaction.
Browser requirements: Microsoft Internet Explorer works 
best, but other browsers (e.g., Firefox) will function satis­
factorily.
Programming language: Java (no version restrictions) for 
the JME applet and for Jmol[36] (to display 3D struc­
tures).
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